Mendell, Jerry R.
Pozsgai, Eric R.
Lewis, Sarah
Griffin, Danielle A.
Lowes, Linda P. http://orcid.org/0000-0003-4206-0557
Alfano, Lindsay N.
Lehman, Kelly J. http://orcid.org/0000-0003-1236-4293
Church, Kathleen
Reash, Natalie F. http://orcid.org/0000-0002-0573-9504
Iammarino, Megan A. http://orcid.org/0000-0003-2800-3855
Sabo, Brenna
Potter, Rachael
Neuhaus, Sarah
Li, Xiaoxi
Stevenson, Herb
Rodino-Klapac, Louise R. http://orcid.org/0000-0002-8966-5177
Funding for this research was provided by:
sarepta therapeutics inc
Article History
Received: 12 August 2022
Accepted: 20 November 2023
First Online: 4 January 2024
Competing interests
: J.R.M. received financial support from Sarepta Therapeutics, Inc. while at NCH at the time of the study and currently is an employee of Sarepta Therapeutics, Inc. E.R.P., S.L., D.A.G., S.N., R.P., X.L., H.S. and L.R.R.-K. are, or have been, employees of Sarepta Therapeutics, Inc. and may own stock/options in the company. L.P.L. and L.N.A. received fees from Sarepta Therapeutics, Inc. for licensure of the LGMD natural history dataset and served on the LGMD advisory board. L.P.L., L.N.A. and N.F.R. perform outcome measures training. B.S., K.J.L., K.C., N.F.R. and M.A.I. have no competing interests to declare and J.R.M with L.R.R.-K., are coinventors of bidridistrogene xeboparvovec.